Comparison
Fisetin vs Ipamorelin
Side-by-side of Fisetin and Ipamorelin. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
Fisetin
Fisetin is a flavonoid found in strawberries with senolytic activity in mouse models. Hickson 2019 confirmed senescent-cell clearance in human adipose tissue.
Ipamorelin
Ipamorelin peptide benefits: selective ghrelin-receptor GHRP, 200 to 300 mcg dosage, GH pulse without cortisol or prolactin rise, CJC-1295 stack vs sermorelin.
Effects at a glance
Fisetin
- •Flavonoid found in strawberries; most potent natural senolytic in screening assays (Yousefzadeh 2018)
- •Hickson 2019 confirmed reduced senescent-cell burden in human adipose tissue at 20 mg/kg pulsed for 2 days
- •Pulsed Mayo protocol (20 mg/kg/day x 2 days monthly) is the only dose with human biomarker evidence
- •Daily low-dose (100-500 mg) is mechanistically weaker but commonly used
- •Low oral bioavailability; with-fat dosing modestly improves absorption
- •Active cancer is a relative contraindication pending clearer polyphenol-treatment data
Ipamorelin
- •Pentapeptide GHS-R1a agonist with the cleanest selectivity profile in the GHRP class
- •Minimal cortisol and prolactin elevation at standard doses (substantially less than GHRP-2 or hexarelin)
- •~2 hour plasma half-life, longest of the synthetic GHRPs
- •Largest human safety database (~600 participants in Helsinn's postoperative ileus phase 2)
- •Standard pairing for CJC-1295 no-DAC at 200 to 300 mcg subcutaneously 2 to 3 times daily
- •Banned by WADA under S2; never reached registration despite phase 2b development
Side-by-side
| Attribute | Fisetin | Ipamorelin |
|---|---|---|
| Category | supplement | peptide |
| Also known as | 3,7,3',4'-tetrahydroxyflavone | NNC 26-0161, Aib-His-D-2-Nal-D-Phe-Lys-NH2 |
| Half-life (hr) ↗ | 2 | 2 |
| Typical dose (mg) ↗ | 500 | 0.2 |
| Dosing frequency | pulsed 2 days/month (Mayo protocol) or daily continuous (empirical) | 2-3x daily |
| Routes | oral | subcutaneous, intravenous |
| Onset (hr) | 1 | 0.25 |
| Peak (hr) | 4 | 1 |
| Molecular weight | 286.24 | 711.86 |
| Molecular formula | C15H10O6 | C38H49N9O5 |
| Mechanism | Senolytic via Bcl-2 family inhibition (Bcl-xL, Bcl-w); broad polyphenol with Nrf2 activation, mTOR inhibition at high concentrations, and antioxidant effects. | Selective GHS-R1a agonist that stimulates pulsatile GH release with minimal cortisol or prolactin co-activation. Suppresses hypothalamic somatostatin and stimulates pituitary somatotrophs. |
| Legal status | OTC dietary supplement | Not FDA approved; advanced through phase 2b in postoperative ileus before discontinuation; research-use-only grey market; banned by WADA |
| WADA status | allowed | banned |
| DEA / Rx | OTC supplement | Not scheduled (research chemical) |
| Pregnancy | Insufficient data | Insufficient data; not recommended |
| CAS | 528-48-3 | 170851-70-4 |
| PubChem CID | 5281614 | 11338566 |
| Wikidata | Q230614 | Q1666741 |
Safety profile
Fisetin
Common side effects
- mild GI upset
- headache (rare)
Contraindications
- active cancer (theoretical, polyphenol interactions)
- pregnancy and lactation (insufficient data)
- concurrent CYP3A4-sensitive medications
Interactions
- statins (CYP3A4 substrates): theoretical reduction in statin clearance at high fisetin doses(minor)
- warfarin: theoretical CYP-mediated interaction; monitor INR if combining(moderate)
- other senolytics (rapamycin, dasatinib + quercetin): additive senolytic effect; pairing is investigational(minor)
Ipamorelin
Common side effects
- injection-site irritation
- vivid dreams
- transient mild head pressure
- occasional headache
Contraindications
- pregnancy
- active malignancy
- history of pituitary tumor
- uncontrolled diabetes
Interactions
- CJC-1295: synergistic GH release via parallel GHRH and ghrelin pathways; standard pairing(minor)
- sermorelin: additive GH release; functionally similar pairing to CJC-1295 with shorter GHRH half-life(minor)
- insulin: sustained GH can blunt insulin sensitivity over weeks(moderate)
- corticosteroids: blunt GH response; reduce expected efficacy(moderate)
Which Should You Take?
Fisetin comes out ahead for most readers on the criteria we weight: 2 catalogued goals, OTC dietary supplement, oral dosing, with a Tier-B outcome catalogued. Ipamorelin is the right call when one of the conditionals below applies.
- → If your priority is healthspan extension, pick Fisetin.
- → If your priority is focus or working memory, pick Fisetin.
- → If your priority is growth-hormone axis, pick Ipamorelin.
- → If your priority is post-training recovery, pick Ipamorelin.
Edge case: If you want to avoid research-only / gray-market sourcing, Fisetin is the more accessible choice.
Default choice: Fisetin. Lower friction to source, and broader goal coverage. Reach for Ipamorelin only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between Fisetin and Ipamorelin?
Fisetin and Ipamorelin differ in category (supplement vs peptide), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, Fisetin or Ipamorelin?
Fisetin half-life is 2 hours; Ipamorelin half-life is 2 hours.
Can you stack Fisetin with Ipamorelin?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper